Antioxidative Actions of Carvedilol in the Treatment of Hypertension
- 1 May 2006
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 2 (2) , 147-151
Abstract
It has been suggested that carvedilol may provide greater benefit than traditional β-blockers in the treatment of chronic heart failure and hypertension because of its antioxidant effects. We have shown that carvedilol inhibits pressure-induced increase in oxidative stress in human coronary smooth muscle cells in culture. We have also shown that carvedilol inhibits oxidative stress of polymorphonuclear cells (PMNs) in spontaneously hypertensive rats independently of blood pressure. We have examined the effect of carvedilol on reactive oxygen species (ROS) formation by PMNs and mononuclear cells (MNCs) in patients with essential hypertension. ROS formation by PMNs and MNCs in hypertensive patients were significantly increased compared with those in normotensive controls. Carvedilol 20mg significantly decreased ROS formation by PMNs and in MNCs. These findings suggest that carvedilol inhibits ROS formation by PMNs and in MNCs. Thus, in vitro, in vivo and human data of antioxidative actions of carvedilol in the treatment of hypertension will be shown.Keywords
This publication has 3 references indexed in Scilit:
- Enhanced oxidative stress in neutrophils from hyperlipidemic guinea pigAtherosclerosis, 2005
- Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertensionThe American Journal of Medicine, 2004
- Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase.Journal of Clinical Investigation, 1986